Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» IMMUTEP
IMMUTEP
Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead
BioSpace
Fri, 07/12/24 - 11:26 am
IMMUTEP
head and neck cancer
eftilagimod alfa
clinical trials
ASCO Preview: Immutep, InxMed and Faron Release New Clinical Findings
BioSpace
Tue, 05/31/22 - 10:49 am
ASCO 2022
IMMUTEP
non-small cell lung cancer
InxMed
ovarian cancer
Faron Pharmaceuticals
solid tumors
After seeing its GSK-backed trial ditched, LAG-3-focused Immutep secures cash, plots new trial push
Fierce Biotech
Mon, 06/21/21 - 11:06 am
IMMUTEP
GSK
funding
Second-quarter catalysts for the smaller players
EP Vantage
Wed, 04/7/21 - 10:25 am
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
GlaxoSmithKline's Immutep-partnered midstage GI med culled in ulcerative colitis
Fierce Biotech
Fri, 01/22/21 - 10:37 am
GSK
R&D
IMMUTEP
ulcerative colitis
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Yahoo/Benzinga
Mon, 10/14/19 - 09:43 am
JNJ
Flexion Therapeutics
Novartis
Amgen
Clearside Biomedical
Alexion
Assertio Therapeutics
Aldeyra Therapeutics
Lineage Therapeutics
IMMUTEP
Marinus Pharma